Home » Posts tagged with » Roche
UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107

UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107

Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer’s Disease drug candidate (AD drug candidate) UCB0107 with Roche and its subsidiary Genentech. UCB0107 is a monoclonal antibody drug candidate, which is being developed by UCB as a potential therapy for patients with progressive supranuclear palsy […]

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 billion for the latter’s cancer drug candidate pralsetinib. Through the deal, Roche gains exclusive rights for the co-development and marketing of the investigational drug for RET-altered cancers across the world […]

Continue reading …
Roche gets FDA nod for cobas EZH2 Mutation Test as companion diagnostic for follicular lymphoma patients

Roche has secured approval from the US Food and Drug Administration (FDA) for its cobas EZH2 Mutation Test as a companion diagnostic for TAZVERIK (tazemetostat), developed by Epizyme. According to the Swiss healthare company, the molecular test can detect abnormalities in the EZH2, or Enhancer of Zeste Homolog 2, gene in patients having follicular lymphoma […]

Continue reading …
Roche acquires DNA sequencing technology company Stratos Genomics

Roche acquisition of Stratos Genomics : Swiss pharma giant Roche has acquired US-based early-stage DNA sequencing technology company Stratos Genomics for an undisclosed price. The transaction is expected to help Roche advance the development of its nanopore sequencer through the access to Sequencing by Expansion (SBX), Stratos Genomics’ unique chemistry. Roche said that once developed, […]

Continue reading …
Roche launches v-TAC blood gas digital solution

Swiss healthcare company Roche has launched a new blood gas digital solution called Roche v-TAC, which is said to be designed to enhance patient care. The new digital diagnostic solution is said to help clinicians to get better results for arterial blood gas values from patients having respiratory or metabolic abnormalities by using a less […]

Continue reading …
Roche cobas HPV test for cervical screening gets FDA nod for use on cobas 6800/8800 Systems

Swiss healthcare company Roche has bagged approval from the US Food and Drug Administration to use its cobas HPV test on the fully automated cobas 6800/8800 Systems for detecting cervical cancer in women. The cobas HPV test has been designed to detect the presence of high-risk human papillomavirus (HPV) DNA in cervical samples from women […]

Continue reading …
Actemra coronavirus clinical trial : Genentech gets FDA nod for COVID-19 trial

Actemra coronavirus clinical trial : Genentech has been given approval by the US Food & Drug Administration (FDA) to undertake the phase 3 COVACTA trial to assess the safety and efficacy of intravenous Actemra (tocilizumab) along with standard of care in hospitalized adults having severe COVID-19 pneumonia. The Roche subsidiary will carry out the randomized, […]

Continue reading …
Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy

Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), an investigational gene therapy for Duchenne muscular dystrophy (DMD). As per the agreement terms, Sarepta Therapeutics will get an upfront payment made up of $750 million in cash and $400 […]

Continue reading …
Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798

Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Roche’s cancer drug Rituxan (rituximab). Rituxan, which is a CD20-directed cytolytic antibody, has approval across various regions for the […]

Continue reading …
Roche to acquire US biotech company Promedior for $1.4bn

Roche acquisition of Promedior : Swiss drugmaker Roche has agreed to acquire Massachusetts-based biotech company Promedior in a deal worth up to $1.39 billion, as per the latest pharma acquisition news. The acquisition will give full rights for the Swiss pharma giant to Promedior’s portfolio of molecules targeting serious fibrotic diseases, including PRM-151, which holds […]

Continue reading …
Page 1 of 212